Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI)
    Meeting Abstract

    Msaouel, P.; Siefker-Radtke, A.; Sweis, R.; Mortazavi, A.; Vogelzang, N.; Vaishampayan, U.; Bradley, T.; Bupathi, M.; Nordquist, L.; Shaffer, D.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: Primary analysis after ≥ 15 months of follow-up from JAVELIN Merkel 200, a registrational phase 2 trial
    Meeting Abstract

    D'Angelo, S.; Lebbé, C.; Mortier, L.; Brohl, A.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G.; Hassel, J.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma
    Meeting Abstract

    D'Angelo, S.; Demetri, G.; Van Tine, B.; Druta, M.; Glod, J.; Chow, W.; Tress, J.; DeYoung, M. P.; Hasan, A.; Wu, Y.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Laminar Wash™ AUTO system: A reliable walk-away sample preparation solution for better TIL recovery without centrifugation
    Meeting Abstract

    Kim, I.; Lye, M.; Zappasodi, R.; Schulze, I.; Eberle, C.; Ke, C. Y.; Cheng, K. L.; Kon, I. C.; Pek, R.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+ previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design
    Meeting Abstract

    D'Angelo, S.; Blay, J. Y.; Chow, W.; Demetri, G.; Thistlethwaite, F.; Wagner, M.; Loeb, D.; Attia, S.; Razak, A.; Haanen, J.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Improving the immunogenicity of modified vaccinia virus Ankara (MVA) vaccine vector by deletion of the vaccinia E5R gene encoding a dominant cGAS inhibitor
    Meeting Abstract

    Deng, L.; Yang, N.; Wang, Y.; Dai, P.; Shuman, S.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Blockade of IDO/TDO downstream effectors restricts a Treg-macrophage suppressive axis and resistance to anti-PD-1 therapy
    Meeting Abstract

    Campesato, L.; Budhu, S.; Tchaicha, J.; Gigoux, M.; Cohen, I.; Mangarin, L.; Redmond, D.; Pourpe, S.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC)
    Meeting Abstract

    Bendell, J.; Rasco, D.; Park, W.; Zhou, L.; Galkin, A.; Slee, D.; Carter, L.; Nickle, D.; Tran, R.; Li, J.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • A phase 2 efficacy and safety trial of ADU-S100 and pembrolizumab in adults with head and neck cancer
    Meeting Abstract

    Cohen, E.; Ferris, R.; Adkins, D.; Zandberg, D.; Dudek, A.; Mathew, M.; Dunn, L.; Grilley-Olson, J.; Sukari, A.; Redman, R.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
    Meeting Abstract

    Abu-Sbeih, H.; Faleck, D.; Ricciuti, B.; Mendelsohn, R.; Naqash, A. R.; Cohen, J.; Sellars, M.; Balaji, A.; Ben-Betzalel, G.; Hajir, I.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save